A Phase 1b trial of PRA023 in moderate-to-severe Crohn's disease
Latest Information Update: 24 Aug 2023
At a glance
- Drugs Tulisokibart (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Prometheus Biosciences
- 19 Jun 2021 New trial record